Sherrie Jill Divito

Sherrie Jill Divito

Auto-generated profile, based on publicly available information

Sherrie Jill Divito

Department of Dermatology, Brigham and Women's Hospital & Harvard Medical School, Boston, Massachusetts, United States of America

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
AMAdèle De Masson
Adèle De Masson
JOJohn T. O’malley
John T. O’malley
CEChristopher P. Elco
Christopher P. Elco
SGSarah S. Garcia
Sarah S. Garcia
SDSherrie J. Divito
Sherrie J. Divito
TKThomas S. Kupper
Thomas S. Kupper
Mycosis fungoides (MF), the most common cutaneous T cell lymphoma (CTCL) is a malignancy of skin-tropic memory T cells. Most MF cases present as early stage (stage I A/B, limited to the skin), and these patients typically have a chronic, indolent clinical course. However, a small subset of early-stage cases develop progressive and fatal disease. Because outcomes can be so different, early identification of this high-risk population is an urgent unmet clinical need. We evaluated the use of next-generation high-throughput DNA sequencing of the T cell receptor β gene (TCRB) in lesional skin biopsies to predict progression and survival in a discovery cohort of 208 patients with CTCL (177 with MF) from a 15-year longitudinal observational clinical study. We compared these data to the results in an independent validation cohort of 101 CTCL patients (87 with MF). The tumor clone frequency (TCF) in lesional skin, measured by high-throughput sequencing of the TCRB gene, was an independent prognostic factor of both progression-free and overall survival in patients with CTCL and MF in particular. In early-stage patients, a TCF of >25% in the skin was a stronger predictor of progression than any other established prognostic factor (stage IB versus IA, presence of plaques, high blood lactate dehydrogenase concentration, large-cell transformation, or age). The TCF therefore may accurately predict disease progression in early-stage MF. Early identification of patients at high risk for progression could help identify candidates who may benefit from allogeneic hematopoietic stem cell transplantation before their disease becomes treatment-refractory.

1 September 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SDSherrie J. Divito
Sherrie J. Divito
AAAnders T. Aasebø
Anders T. Aasebø
TMTiago R Matos
Tiago R Matos
PHPei-Chen Hsieh
Pei-Chen Hsieh
MCMatthew Collin
Matthew Collin
TKThomas S. Kupper
Thomas S. Kupper
Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in hematopoietic stem cell transplantation (HSCT). Donor T cells are key mediators in pathogenesis, but a contribution from host T cells has not been explored, as conditioning regimens are believed to deplete host T cells. To evaluate a potential role for host T cells in GVHD, the origin of skin and blood T cells was assessed prospectively in patients after HSCT in the absence of GVHD. While blood contained primarily donor-derived T cells, most T cells in the skin were host derived. We next examined patient skin, colon, and blood during acute GVHD. Host T cells were present in all skin and colon acute GVHD specimens studied, yet were largely absent in blood. We observed acute skin GVHD in the presence of 100% host T cells. Analysis demonstrated that a subset of host T cells in peripheral tissues were proliferating (Ki67+) and producing the proinflammatory cytokines IFN-γ and IL-17 in situ. Comparatively, the majority of antigen-presenting cells (APCs) in tissue in acute GVHD were donor derived, and donor-derived APCs were observed directly adjacent to host T cells. A humanized mouse model demonstrated that host skin-resident T cells could be activated by donor monocytes to generate a GVHD-like dermatitis. Thus, host tissue-resident T cells may play a previously unappreciated pathogenic role in acute GVHD.

1 January 2016 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
GRGeorge A. Romar
George A. Romar
TKThomas S. Kupper
Thomas S. Kupper
SDSherrie J. Divito
Sherrie J. Divito

9 November 2021 in Current Dermatology Reports
Verified
Journal Article
Closed access
PDF file
ESElisa Maria Schunkert
Elisa Maria Schunkert
SDSherrie Jill Divito
Sherrie Jill Divito

20 December 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
TCTafadzwa Chimbetete
Tafadzwa Chimbetete
CBChloe Buck
Chloe Buck
PCPhuti Choshi
Phuti Choshi
RSRose Selim
Rose Selim
SPSarah Pedretti
Sarah Pedretti
JPJonny Peter
Jonny Peter

23 August 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
ESElisa Maria Schunkert
Elisa Maria Schunkert
PSPranali Nitin Shah
Pranali Nitin Shah
SDSherrie Jill Divito
Sherrie Jill Divito
Delayed-type drug hypersensitivity reactions (dtDHR) are immune-mediated reactions with skin and visceral manifestations ranging from mild to severe. Clinical care is negatively impacted by a limited understanding of disease pathogenesis. Though T cells are believed to orchestrate disease, the type of T cell and the location and mechanism of T cell activation remain unknown. Resident memory T cells (TRM) are a unique T cell population potentially well situated to act as key mediators in disease pathogenesis, but significant obstacles to defining, identifying, and testing TRMin dtDHR preclude definitive conclusions at this time. Deeper mechanistic interrogation to address these unanswered questions is necessary, as involvement of TRMin disease has significant implications for prediction, diagnosis, and treatment of disease.